Get the Stockscreener App
91.65
1.98%
-1.85
After Hours:
91.65
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc Stock (ALC) Latest News
Alcon: An Eyecare Leader With Strong Profit Margins, But Overheated Valuation - Seeking Alpha
Alcon Laboratories is considering a major $100M expansion of its Fort Worth campus - AOL
Alcon Loses Bid to Veto Aurion IPO, Can Still Oppose Listing (1) - Bloomberg Law
Intraocular Lens Market Forecast and Company Analysis Report 2025-2033 Featuring Alcon, Bausch Health, Hoya, Johnson & Johnson, STAAR Surgical Co, Carl Zeiss Meditec, and Novartis - GlobeNewswire
Alcon stock price target cut to $106 by Needham, maintains Buy - MSN
Alcon Breaks Above 200-Day Moving AverageBullish for ALC - Nasdaq
Artificial Tears Market Overall Study Report 2025-2032 | - openPR
Alcon stock price target cut to $105 by KeyBanc - MSN
Apple To $253? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Do Options Traders Know Something About Alcon (ALC) Stock We Don't? - Yahoo Finance
First Week of March 21st Options Trading For Alcon (ALC) - Nasdaq
Alcon Inc (ALC) Shares Up 3.7% on Jan 21 - GuruFocus.com
Modernizing a Legacy Application on AWS Serverless with Alcon - AWS Blog
Modernizing a Legacy Application on AWS Serverless with Alcon | Case Study | AWS - AWS Blog
Alcon to Seek M&A -January 14, 2025 at 07:30 pm EST - Marketscreener.com
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - Yahoo Finance
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Redburn raises Alcon stock rating to Buy By Investing.com - Investing.com Australia
Redburn raises Alcon stock rating to Buy - Investing.com
Dry Eye Disease Market Is Booming Worldwide 2025-2032 | Novartis - openPR
Contact Lens Market Deep Research Report with Forecast by 2031 | Bausch & Lomb Incorporated, Alcon Vision LLC - EIN News
Alcon Inc. (VTX:ALC) is favoured by institutional owners who hold 63% of the company - Simply Wall St
Seeing Brilliance in APAC: Alcon’s Vision Care Innovations and Eye Health Mission - BSA bureau
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Alcon Laboratories issues recall for Systane eye drops due to fungal contamination - Top Class Actions
News Release – DOH Issues Recall Alert For Alcon Laboratories Systane Brand Lubricant Eye Drops Due to Fungal - EIN News
DOH issues recall alert for Alcon Laboratories Systane Brand Lubricant Eye Drops - Maui Now
Alcon Labs recalling eye drops - Valley News
Alcon Laboratories Recalls Systane Eye Drops Nationwide Over Fungal Contamination Risk - Black Enterprise
Alcon's (VTX:ALC) investors will be pleased with their respectable 41% return over the last five years - Simply Wall St
Alcon recalls Systane eye drops due to potential fungal contamination risk - WRAL News
Alcon Laboratories Recalls Systane Eye Drops Over Fungal Risk - Franklin County Free Press
Alcon Labs Recalls Systane Lubricant Eye Drops Over Fungal Contamination - Nasdaq
Refractive Surgery Market Growth in Future Scope 2024-2031 | - openPR
Retinal Laser Photocoagulation Market Top PlayersAlcon, A.R.C Laser, Ellex Medical, Carl Zeiss, Quantel Medical. - openPR
Here's Why Alcon (ALC) is a Strong Growth Stock - MSN
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer - GlobeNewswire
Alcon Laboratories Issues Voluntary Nationwide Recall of One (1) Lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count (Lot 10101), Due to Fungal Contamination - US Recall News
Alcon a top pick for 2025 at Needham on upcoming product launches - MSN
Alcon Top Pick for 2025 at Needham, added to Conviction List - MSN
2.23%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):